Dyne Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Dyne Therapeutics, Inc. on March 3, 2022, reporting events that occurred on March 2, 2022. The Company is a Delaware corporation with its principal executive offices in Waltham, Massachusetts, and its common stock trades on the Nasdaq Global Select Market under the symbol "DYN".
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. This report focuses exclusively on corporate governance and director compensation.
Material Changes
On March 2, 2022, the Board of Directors elected Carlo Incerti, M.D., as a Class I independent director. His term will last until the 2024 Annual Meeting of Stockholders or until his successor is elected. Dr. Incerti has not been appointed to any Board committees.
Compensatory Arrangements and Governance
- Equity Grant: Upon election, Dr. Incerti received an option to purchase 39,139 shares of common stock at an exercise price of $8.69 per share (the closing price on the grant date).
- Vesting Schedule: The option vests in equal monthly installments over three years, contingent on continued service. Full acceleration occurs in the event of a change in control.
- Cash Compensation: Dr. Incerti will receive annual cash compensation of $35,000 as a Board member.
- Other Benefits: Includes annual equity grants per the director compensation program and reimbursement for reasonable travel and out-of-pocket expenses.
- Indemnification: Dr. Incerti will enter into the Company's standard form of indemnification agreement.
Investor Verification Checklist
- Verify the independence status of Dr. Incerti under Nasdaq rules.
- Confirm the total number of outstanding options granted under the 2020 Stock Incentive Plan.
- Review the Company's 2020 Stock Incentive Plan terms regarding change in control provisions.
- Check for any subsequent filings regarding Dr. Incerti's committee assignments or resignation.